Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

12.55USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$12.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
203,839
52-wk High
$19.90
52-wk Low
$11.85

Select another date:

Wed, Nov 1 2017

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

Momenta, Sandoz face off with Amphastar in blockbuster drug patent trial

Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit took Amphastar Pharmaceuticals Inc to trial Tuesday in a long-running suit over patent infringement that seeks hundreds of millions of dollars in damages over Amphastar's generic version of the blockbuster blood-thinner Lovenox.

Select another date: